Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZUMA-4 crono
- Development stage
- Unknown
- Lead developer
- Bio-STILOGIT Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
AZUMA-4 crono is a multi-ingredient dietary supplement developed by Bio-STILOGIT Pharmaceuticals, primarily marketed in Italy for the support of prostate health and urinary tract function. The formulation typically contains botanical extracts such as *Serenoa repens* (Saw Palmetto) and *Boswellia serrata*, along with essential minerals including Zinc and Selenium. The "crono" designation refers to a controlled-release delivery system designed to optimize the absorption and bioavailability of its active components over an extended period. It is commonly used to manage symptoms associated with benign prostatic hyperplasia (BPH) and to promote the physiological drainage of body fluids.
- Brand names
- AZUMA-4 cronoAZUMA4 cronoAZUMA 4 crono
- Other names
- AZUMA-4AZUMA4AZUMA 4
02
Targets
Steroidogenesis (Steroidogenic enzymes)Eicosanoid synth (Eicosanoid biosynthesis)
Beyond the preview
Go deeper on AZUMA-4 crono.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZUMA-4 crono.